Physician profile
Christopher V Boudakian
NPI 1396005849
$3,824.32
in general payments reported to CMS, 2019-2025
14 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 90% of Spinal Cord Injury Medicine providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $824 · 2021: $498 · 2022: $135 · 2023: $232 · 2024: $104 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Travel and Lodging: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.71 |
| Travel and Lodging | $449.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,085.14 | 2019-2020 | |
| Medtronic, INC. | $1,017.07 | 2023-2025 | Synchromedii, Intellis Adaptivestim |
| Ipsen Biopharmaceuticals, INC | $477.28 | 2021-2025 | Dysport |
| Amgen INC. | $353.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $157.49 | 2021 | |
| Coloplast Corp | $149.50 | 2021 | |
| Amneal Pharmaceuticals LLC | $132.13 | 2022-2023 | Lioresal (Baclofen) |
| Saol Therapeutics INC. | $116.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $111.36 | 2019 | |
| Abc Home Medical Supply, INC. | $79.82 | 2023 | |
| Abbvie INC. | $69.48 | 2022-2025 | |
| Microtransponder, INC. | $27.77 | 2025 | |
| Medtronic Vascular, INC. | $24.87 | 2019 | |
| Allergan, INC. | $21.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boudakian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.